Effects of intravenous laser blood irradiation on sympathoadrenal activity and endothelial dysfunction in resistant hypertension

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Resistant hypertension is strongly associated with an increased risk of cardiovascular complications, poor prognosis, and reduced quality of life, remaining a major global medical and social challenge. Standard antihypertensive therapy is often insufficiently effective. In this context, physiotherapeutic methods such as intravenous laser blood irradiation, known for its pleiotropic effects, represent a promising therapeutic approach.

AIM: To evaluate the impact of intravenous laser blood irradiation as an adjunctive treatment to standard antihypertensive therapy on the achievement of target blood pressure levels and plasma levels of β-adrenergic reactivity of erythrocyte membranes (β-AREM), nitric oxide (NO), and endothelin-1 (ET-1) in patients with resistant hypertension.

MATERIALS AND METHODS: The study included 100 ambulatory patients aged 18–45 years with resistant hypertension, randomized into: main group (n=50, receiving intravenous laser blood irradiation in addition to standard antihypertensive therapy) and comparison group (n=50, receiving only standard antihypertensive therapy). Assessments were conducted at baseline and after two months, including: 24-hour BP monitoring, plasma β-AREM, NO, and ET-1 levels. The control group (n=45) included patients with controlled hypertension.

RESULTS: After two months, the main group demonstrated a statistically significant improvement in number of patients achieving target BP levels (p <0.05), as well as in β-AREM (p=0.002), NO (p=0.028), ET-1 (p=0.006).

CONCLUSION: Intravenous laser blood irradiation may serve as an effective adjunctive therapy in the pathogenetically oriented management of resistant hypertension in outpatient settings.

Full Text

Restricted Access

About the authors

Roman R. Zvegintsev

V.I. Vernadsky Crimean Federal University

Author for correspondence.
Email: romamuse97@gmail.com
ORCID iD: 0009-0001-7161-1701
SPIN-code: 3805-4367
Russian Federation, Simferopol

References

  1. Williams B, Mancia G, Spiering W, et al. 2018 practice guidelines for the management of arterial hypertension of the European society of cardiology and the European society of hypertension ESC/ESH task force for the management of arterial hypertension. J Hypertens. 2018;36(12):2284–2309. doi: 10.1097/HJH.0000000000001961 EDN: HJMENB
  2. Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105:98–105. doi: 10.1136/heartjnl-2018-313599 EDN: LPMTGE
  3. Kuz'min OB, Beljanin VV, Buchneva NV, et al. New drugs for the treatment of resistant hypertension: nonsteroidal mineralcorticoid receptor antagonist finerenone and aldosterone synthase inhibitor baxdrostat. Arterial'naja gipertenzija. 2024;30(4):364–372. doi: 10.18705/1607-419X-2024-2393 EDN: XKFDMC
  4. Bakris G, Chen C, Campbell AK, et al. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens. 2023;25(8):737–747. doi: 10.1111/jch.14701 EDN: MCUKIZ
  5. Orehov AJu, Karazhanova LK. The role of the sympathetic nervous system in resistant hypertension: pathophysiological and clinical aspects. Arterial'naja gipertenzija. 2022;28(4):348–356. doi: 10.18705/1607-419X-2022-28-4-348-356 EDN: ZSAOYT
  6. Cafronenko AV, Gancgorn EV. Endothelial dysfunction at refractory arterial hypertension. South russian journal of therapeutic practice. 2021;2(2):26–33. doi: 10.21886/2712-8156-2021-2-2-26-33 EDN: PETBYS
  7. Babushkina IV, Sergeeva AS, Pivovarov JuN, et al. Structural and functional properties of vascular endothelium. Kardiologija. 2015;55(2):82–6. doi: 10.18565/cardio.2015.2.82-86 EDN: TNAGZB
  8. Houde M, Desbiens L, D'Orléans-Juste P. Endothelin-1: biosynthesis, signaling and vasoreactivity. Adv Pharmacol. 2016;77:143–75. doi: 10.1016/bs.apha.2016.05.002
  9. Huang Y, Zhang H, Shao Z, et al. Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta. Cardiovasc Res. 2011;90(2):267–75. doi: 10.1093/cvr/cvq401 EDN: OLASHT
  10. Rebrova TJu, Ripp TM, Afanas'ev SA, et al. Possibility of evaluating the effectiveness of renal artery sympathetic denervation in resistant hypertension early after radiofrequency ablation. Terapevticheskij arhiv. 2016;88(8):10–13. doi: 10.17116/terarkh201688810-13 EDN: WKGCBD
  11. Ripp TM, Rebrova TJu, Mordovin VF, et al. Criteria for selecting patients with resistant hypertension for a renal sympathetic denervation. Terapevticheskij arhiv. 2016;88(8):14–18. doi: 10.17116/terarkh201688814-18 EDN: WKGCBN
  12. Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (precision): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400:1927–1937. doi: 10.1016/S0140-6736(22)02034-7 EDN: KQTAHZ
  13. Rajapakse NW, Giam B, Kuruppu S, et al. Impaired l-arginine-nitric oxide pathway contributes to the pathogenesis of resistant hypertension. Clin Sci. 2019;30;133(20):2061–2067. doi: 10.1042/CS20190851
  14. Zjubanova IV, Fal'kovskaja AJu, Mordovin VF, et al. Erythrocyte membranes beta-adrenoreactivity changes after renal denervation in patients with resistant hypertension, relationship with antihypertensive and cardioprotective intervention efficacy. Kardiologija. 2021;61(8):32–39. doi: 10.18087/cardio.2021.8.n1556 EDN: OBPRRC
  15. Nechaeva GI, Moskvina JuV. Adrenoreactivity in patients with arrhythmic syndrome associated with connective tissue dysplasia at the background of intake of the magnezium orotate. Kardiologija. 2011;3:54–57. EDN: NZKGBJ
  16. Khalaf D, Krüger M, Wehland M, et al. The effects of oral L-arginine and L-citrulline supplementation on blood pressure. Nutrients. 2019;11(7):1679. doi: 10.3390/nu11071679 EDN: UVPVBF
  17. Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338:784–791. doi: 10.1056/NEJM199803193381202
  18. Horinouchi T, Terada K, Higasti T, Miwa S. Endothelin receptor signaling: new insight into its regulatory mechanisms. J Pharmacol Sci. 2013;123:85–101. doi: 10.1254/jphs.13r02cr EDN: YECNDN
  19. Shishonin AJu, Galiev JeA, Jakovleva EV, et al. Physical methods of correction of arterial hypertension: modern concepts. (a literature review). Problems of balneology, physiotherapy, and exercise therapy. 2024;101(3):41–47. doi: 10.17116/kurort202410103141
  20. Ismailov EL, Kokurov AL, Sauleeva ZhK. The use of intravascular laser irradiation of blood in patients with hypertension. Vestnik Kazahskogo Nacional'nogo medicinskogo universiteta. 2016;1:319–321. EDN: YKOMBX
  21. Prjadko NJu, Djachenko AV, Prjadko NN, Bikmetova GM. Experience of using quantum hemotherapy (VLOC) in the treatment of patients with hypertension. Bulletin of Physiotherapy and Balneology. 2018;24 (1):126–126. (In Russ.) EDN: XQWTMT
  22. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. 2024 clinical practice guidelines for hypertension in adults. Russian journal of cardiology. 2024;29(9):6117. doi: 10.15829/1560-4071-2024-6117 EDN: GUEWLU
  23. Mikhaylov VA. Use of the intravenous frequency laser therapy (IFLT) of 640 nm in the complex treatment of the nervous system and brain diseases. International Conference on Clinical and Medical Case Reports. 2019;8:19–20. doi: 10.33552/ANN.2021.11.000769
  24. Mikhaylov VA. The use of Intravenous Laser Blood Irradiation (ILBI) at 630–640 nm to prevent vascular diseases and to increase life expectancy. Laser Ther. 2015;24(1):15–26. doi: 10.5978/islsm.15-OR-02 EDN: WRAPTV
  25. Kashiwagi S, Morita A, Yokomizo S, et al. Photobiomodulation and nitric oxide signaling. Nitric Oxide. 2023;130:58–68. doi: 10.1016/j.niox.2022.11.005 EDN: BFKQWO
  26. Chuang Y-C, Cheng Y-Y. Application of intravenous laser irradiation of blood (ILIB) in physical medicine: a narrative review. Rehabilitation Practice and Science. 2024;2024(1). doi: 10.6315/3005-3846.2230 EDN: WIINLB

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86508 от 11.12.2023. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80650 от 15.03.2021 г.